437991-39-4Relevant academic research and scientific papers
SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF
-
Page/Page column 9, (2009/02/11)
LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRalpha subtype rather than LXRbeta, which suggests that LXRbeta-selective agonists are attractive candidates for modulation of human lipid metabolism. The present application provides novel LXRbeta-selective ligands that preferably modulate LXRbeta over LXRalpha. These ligands may be used to treat a variety of diseases associated with LXR, such as for example lipid metabolism disorders, atherosclerosis, Alzheimer disease, and inflammation.
